US Bancorp DE lifted its position in shares of Steris PLC (NYSE:STE) by 288.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 33,966 shares of the medical equipment provider’s stock after purchasing an additional 25,229 shares during the period. US Bancorp DE’s holdings in Steris were worth $2,971,000 at the end of the most recent reporting period.
Other institutional investors have also recently added to or reduced their stakes in the company. Zions Bancorporation purchased a new stake in shares of Steris during the 3rd quarter worth $178,000. Citigroup Inc. purchased a new stake in shares of Steris during the 2nd quarter worth $206,000. Oakbrook Investments LLC purchased a new stake in shares of Steris during the 4th quarter worth $271,000. GSA Capital Partners LLP purchased a new stake in shares of Steris during the 3rd quarter worth $284,000. Finally, Atria Investments LLC purchased a new stake in shares of Steris during the 4th quarter worth $292,000. 89.47% of the stock is owned by institutional investors and hedge funds.
In related news, VP Sudhir K. Pahwa sold 2,000 shares of Steris stock in a transaction on Monday, January 29th. The shares were sold at an average price of $92.09, for a total transaction of $184,180.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Karen L. Burton sold 1,500 shares of Steris stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $85.59, for a total transaction of $128,385.00. The disclosure for this sale can be found here. 2.55% of the stock is owned by company insiders.
Shares of Steris PLC (NYSE STE) opened at $88.33 on Thursday. Steris PLC has a one year low of $67.55 and a one year high of $93.71. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.22 and a current ratio of 2.82. The company has a market cap of $7,530.00, a price-to-earnings ratio of 31.10 and a beta of 1.22.
Steris (NYSE:STE) last announced its quarterly earnings results on Wednesday, February 7th. The medical equipment provider reported $1.12 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.07 by $0.05. Steris had a net margin of 9.42% and a return on equity of 11.57%. The firm had revenue of $661.90 million for the quarter, compared to analyst estimates of $663.17 million. During the same period last year, the business earned $0.98 EPS. Steris’s revenue for the quarter was up 2.3% compared to the same quarter last year. analysts predict that Steris PLC will post 4.13 earnings per share for the current fiscal year.
STE has been the subject of several recent analyst reports. Zacks Investment Research cut shares of Steris from a “buy” rating to a “sell” rating in a research report on Monday, November 6th. KeyCorp reaffirmed an “overweight” rating and set a $101.00 price objective (up from $91.00) on shares of Steris in a research report on Thursday, November 2nd. Raymond James Financial reaffirmed a “market perform” rating and set a $100.00 price objective on shares of Steris in a research report on Wednesday, January 3rd. Northcoast Research set a $102.00 price objective on shares of Steris and gave the stock a “buy” rating in a research report on Thursday, February 8th. Finally, TD Securities lifted their price objective on shares of Steris from C$14.00 to C$16.00 and gave the stock a “buy” rating in a research report on Thursday, November 9th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $84.80.
COPYRIGHT VIOLATION WARNING: This story was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/15/steris-plc-ste-stake-raised-by-us-bancorp-de.html.
Steris Company Profile
STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others.
Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.